Cardiovascular CROs in Netherlands

Global CRO built exclusively for MedTech, integrating regulatory strategy, clinical development, and market access reimbursement for device and IVD programs from the Netherlands since 1988.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.

Netherlands-based CRO providing Phase I clinical pharmacology, bioequivalence, and early-phase clinical trial services as the European arm of India's Veeda Group.